Observational studyYonsei medical journal2026
Evaluation of Rabeprazole for Gastrointestinal Protection in Acute Coronary Syndrome Patients Treated with Aspirin and Ticagrelor: A Pilot Study.
Observational study in Yonsei medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePatients with acute coronary syndrome (ACS) on ticagrelor-based dual antiplatelet therapy (DAPT) have an increased risk of gastrointestinal (GI) bleeding. However, evidence supporting the protective role of proton pump inhibitors against DAPT-induced gastric mucosal injury remains limited. MATERIALS AND
methodsThis was a single-center, prospective, open-label, observational trial enrolling patients with ACS who were treated with DAPT, specifically aspirin and ticagrelor, following percutaneous coronary intervention in South Korea. Participants received 20 mg rabeprazole once daily for 8 weeks. The primary outcome was the proportion of patients exhibiting a modified Lanza score (MLS) of 0-5 on upper endoscopy at 8 weeks compared to baseline endoscopy results. The secondary outcomes included GI symptom scores and safety assessments.
resultsAmong the 50 patients included in the per-protocol analysis, the median MLS at baseline and 8 weeks was 2.0 (1.0-2.0) and 2.0 (1.0-2.0), respectively, with no significant change (
conclusionIn this pilot study, rabeprazole was associated with maintained gastric mucosal integrity in patients with ACS receiving ticagrelor-based DAPT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.